Results from the DESTINY-Breast12 Phase IIIb/IV trial reveal that Enhertu (trastuzumab deruxtecan) demonstrated significant overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, including those with brain metastases who had undergone no more than two previous lines…
Pfizer Inc. (NYSE: PFE) continues to highlight groundbreaking research and next-generation therapies from its comprehensive Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, held from September 13-17 in Barcelona. The company will present data from over…
Eli Lilly and Company (NYSE: LLY) today released detailed findings from the QWINT-5 phase 3 trial, which compared once-weekly insulin efsitora alfa (efsitora) to daily insulin degludec in adults with type 1 diabetes. These patients required both daily basal insulin…
Oisín Biotechnologies, a privately held company dedicated to addressing age-related diseases, has announced the publication of preclinical data from its follistatin (FST) gene therapy program. The findings, detailed in the article “Safe and Effective Delivery of DNA and RNA Using…
Novotech, a leading global full-service Contract Research Organization (CRO), has been honored with the 2024 Global Company of the Year Award by Frost & Sullivan. This prestigious accolade highlights Novotech’s dedication to enhancing clinical development for biotech firms through cutting-edge…
CorFlow Therapeutics AG has secured €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners. The funding round also saw participation from 415 Capital, CorFlow’s initial investor and largest shareholder, alongside Merieux Equity Partners, Laerdal Million Lives…
Over 187,000 children under ten in central Gaza received the novel oral polio vaccine type 2 (nOPV2) during the first phase of a two-round polio vaccination campaign held from September 1–3, 2024. This phase surpassed the initial target of 157,000…
The World Health Organization (WHO) has officially designated the EngAGE Centre for Research in Ageing at Trinity College Dublin as its new Collaborating Centre for Longitudinal Studies on Ageing and the Life Course. This new Collaborating Centre will play a…
An exploratory analysis of the TROPION-Lung01 Phase III trial revealed that TROP2, as measured by AstraZeneca’s advanced computational pathology platform—quantitative continuous scoring (QCS)—was a predictor of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated…
AstraZeneca has finalized the studies supporting the regulatory filings for Breztri/Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) to transition to a new, next-generation propellant. This propellant has a 99.9% lower Global Warming Potential compared to those used in current inhaled medications.…
Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to present new 48-week data on its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place…
Interim results from the ongoing IDeate-Lung01 phase 2 trial show that ifinatamab deruxtecan (I-DXd) continues to deliver promising objective response rates in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). These findings, part of a press conference today, will…